Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab maintenance for high-risk aggressive B-cell lymphoma in first remission
MOH_2018-06-10_002439Phase 2Not yet recruiting
- Sponsor
- דר' מירב קדמי
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in diffuse large B-cell lymphoma (DLBCL) and aggressive B-cell lymphoma, sponsored by דר' מירב קדמי. Primary endpoint: Disease-free survival at 3 years from diagnosis. Planned start May 2018; status: not yet recruiting.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)aggressive B-cell lymphoma
Beyond the preview
Go deeper on MOH_2018-06-10_002439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-10_002439.